Anti-Xa activity in apixaban overdose: a case report

被引:14
|
作者
Barton, James [1 ]
Wong, Anselm [1 ,2 ]
Graudins, Andis [1 ,2 ]
机构
[1] Monash Hlth, Monash Clin Toxicol, Program Emergency Med, Clayton, Vic, Australia
[2] Monash Univ, Fac Med Nursing & Hlth Sci, Monash Hlth, Sch Clin Sci, Clayton, Vic 3800, Australia
关键词
Factor Xa inhibitors; oral anticoagulants; toxicokinetics; RIVAROXABAN; INHIBITOR; PHARMACOKINETICS; ASSAYS; PHARMACODYNAMICS; PROTHROMBIN; REVERSAL; SAFETY; GUIDE;
D O I
10.1080/15563650.2016.1204453
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Introduction: Apixaban is a novel oral anticoagulation agent that exerts its effect through direct factor Xa inhibition. We present a case of multi-drug overdose including apixaban with associated apixaban concentrations.Case: A 53 year-old man presented to our metropolitan hospital following a deliberate self-poisoning with 200mg apixaban, 35mg ramipril, 105mg bisoprolol, 280mg atorvastatin, 6mg colchicine, 37.4mg magnesium, 4x500mg paracetamol/9.5mg codeine/5mg phenylephrine and alcohol. He developed hypotension that was treated with noradrenaline. His initial and peak apixaban concentration was 1022.6ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression. Vitamin K 10mg (at 9h post-ingestion) and Prothrombinex-VF 2000 units (at 13h post-ingestion) were also administered without any observed effect on coagulation studies. Apixaban elimination appeared to display first-order kinetics with an elimination half-life of 7.4h. His plasma apixaban concentration was within the therapeutic dose range 10h post-ingestion and he recovered uneventfully.Conclusion: A case of apixaban overdose with associated apixaban concentrations is presented. There was rapid resolution of anticoagulation with no demonstrable benefit of currently available clotting factor replacement.
引用
收藏
页码:871 / 873
页数:3
相关论文
共 50 条
  • [1] Apixaban anti-Xa levels in clinical practice: A case report
    Clark, Sarah
    Alcala-Zermeno, Juan Luis
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
  • [2] Measurement of anti-Xa activity of apixaban in plasma
    Samama, M. M.
    Guinet, C.
    Le Flem, L.
    Amiral, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 826 - 827
  • [3] Comparison of apixaban and rivaroxaban trough anti-Xa activity.
    Bookstaver, David
    Sparks, Kimberly
    Pybus, Brandon
    Davis, Dustin
    PHARMACOTHERAPY, 2016, 36 (12): : E239 - E239
  • [4] Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban
    Bookstaver, David A.
    Sparks, Kimberly
    Pybus, Brandon S.
    Davis, Dustin K.
    Marcsisin, Sean R.
    Sousa, Jason C.
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (03) : 251 - 256
  • [5] ASSESSMENT OF APIXABAN PLASMA LEVELS BY ANTI-XA ACTIVITY TESTS: COMPARISON OF ROTACHROM AND STA LIQUID ANTI-XA ASSAYS
    Wang, Zhaoqing
    Green, George
    Connolly, Thomas
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (06) : E76 - E77
  • [7] Heparin interference in anti-XA assays for rivaroxaban and apixaban
    Cutsforth, G. A.
    Finnegan, K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 795 - 795
  • [8] LABORATORY VALIDATION OF A CHROMOGENIC ANTI-XA ASSAY FOR APIXABAN
    Leger, Rachel R.
    Tange, Julie I.
    McBane, Robert D.
    Chen, Dong
    Pruthi, Rajiv K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (09) : E36 - E37
  • [9] Observed Apixaban Anti-Xa Levels in Obese Patients
    Harkness, Weston
    Pipitone, Olivia
    Joss, Jacqueline
    Schiedler, Michael
    Shagavah, Santon
    Moore, Ryan
    Hsing, Jeff
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (11) : 1215 - 1221
  • [10] STUDIES OF ANTI-XA ACTIVITY
    SCULLY, MF
    ELLIS, V
    KAKKAR, VV
    THROMBOSIS RESEARCH, 1983, 29 (03) : 387 - 388